International Stem Cell Corporation (ISCO)

OTCMKTS: ISCO · Delayed Price · USD
0.00 (0.00%)
Mar 22, 2023, 3:14 PM EDT - Market closed
Market Cap 1.66M
Revenue (ttm) 7.59M
Net Income (ttm) -705,000
Shares Out 8.00M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 31
Open 0.190
Previous Close 0.190
Day's Range 0.190 - 0.190
52-Week Range 0.110 - 0.540
Beta 0.65
Analysts n/a
Price Target n/a
Earnings Date n/a

About ISCO

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in North America, Asia, Europe, and internationally. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; and develops, manufactures, and markets anti-aging skincare and human cell culture products. T... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 26
Stock Exchange OTCMKTS
Ticker Symbol ISCO
Full Company Profile

Financial Performance

In 2021, ISCO's revenue was $7.18 million, an increase of 0.67% compared to the previous year's $7.13 million. Losses were -$899,000, -67.00% less than in 2020.

Financial Statements


International Stem Cell Corporation Announces Strong Financial Results for the Quarter Ended March 31, 2022

SAN DIEGO, CA / ACCESSWIRE / May 17, 2022 / International Stem Cell Corporation (OTC PINK:ISCO) ( ("ISCO" or "the Company"), a California-based clinical stage biotechnolo...

11 months ago - Accesswire